AUA 2023: Bladder Cancer Content

AUA 2023: Focus on Bladder Cancer

The relevant updates to the guideline for upper tract urothelial carcinoma are provided by Dr. Peter Clark.

There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.

During an afternoon plenary session, Dr. Jonathan Coleman presented the updates to the AUA guideline for UTUC.

Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.

IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC.

Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial.

A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.

A newly developed model for prediction of 90-day mortality after radical cystectomy has outperformed available nomograms.

Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.

The AUA has released their 2023 clinical practice guideline for the diagnosis and treatment of nonmetastatic UTUC.

A study analyzed effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical BCG.

TAR-200 consists of a small silicone delivery system that provides sustained, local release of gemcitabine to the bladder.